Sentence examples for further time points from inspiring English sources

Given the prolonged timing required by human neural progenitors to mature in vivo, analysis at further time points could provide additional details on the functional integration of transplanted cells in the damaged neuronal circuitry.

SUR and SUV measured at the respective reference time were used as the 'gold standard' against which the corrected uptake values acquired at further time points were compared.

But at further time points, when the cells completely migrate throughout the scaffolds, this is the probability for the cells in bridging over the nanofibrous layers which effect the proliferation value.

While at further time points, when slow but continuous diffusion was occurred, because of more distant placement of nanofibers toward each other as the result of more in-between microparticles, exposure of nanofibers and PBS solution intensified and overall PBS uptake values increased because of more polymer adsorption possibility.

Further time points could not be examined because nearly all sensory-deprived isolated bees had died by 21 days.

It is possible that this effect diminishes over the passage of time (Experiment 2) although further research is needed to study further time points.

Further research would be required to determine whether women need to be reassessed at least at one further time point to determine changes to risk related to menopausal status, mammographic density, and other changes to risk factors.

The latter accounts for experimental uncertainty, error and chance [16], [17], [18], and confirmed that not only the model accurately predicts actual responses but also that an additional dose in the model did not enhance the accuracy of the system, while the integration of a further time-point had only a minimal effect.

Medication data were collected at baseline and at two further time-points for eligible residents of six care homes participating in the EVIDEM-End Of Life (EOL) study for whom medication administration records were available.

Our study has some limitations and we thus plan to study in the future further time-points at 1 year or beyond, the use of a booster dose to examine immune memory and antigen-specific in-vitro B-cell studies.

The eligible study population comprised all residents from six residential care homes participating in the EVIDEM-End Of Life (EOL) study for whom medication administration records were available at baseline and at the two further time-points (approximately sixteen weeks apart) at which data were collected over the 12-month data collection period.